This 1-hour webinar will provide the latest updates on T1D autoantibody screening tests and programs, their role in identifying people who have a risk of developing T1D, best practices for monitoring and supporting patients following T1D autoantibody testing, and investigational therapies that may slow T1D progression in individuals with a high risk of developing T1D and those with new-onset T1D.
Upon completion, participants should be able to:
- Recognize the different stages of T1D and the importance of preventing T1D diagnosis in diabetic ketoacidosis
- Explain the benefits and limitations of T1D autoantibody screening tests to patients and families
- Describe monitoring protocols and support resources for individuals who have tested positive for T1D autoantibodies
- Identify therapies currently in clinical trials that may slow T1D progression in individuals with a high risk of developing T1D and in those with new onset T1D
This activity was developed by Med-IQ in collaboration with ACOFP and JDRF.
This activity is supported by an educational grant from Provention Bio.
The American College of Osteopathic Family Physicians (ACOFP) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. ACOFP designates this program for a maximum number of 1.0 AOA Category 1-A credits and will report CME with the extent of the physician’s participation in this activity.
This program is sponsored by ACOFP for educational purposes only. The material presented is not intended to represent the sole or best medical interventions for the discussed diagnoses, but rather is intended to present the opinions of the authors or presenters that may be helpful to other practitioners. Attendees participating in this medical education program do so with the full knowledge that they waive any claim they may have against ACOFP for reliance on any information presented during these educational activities.